Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sofosbuvir + velpatasvir + voxilaprevir
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Sofosbuvir + velpatasvir + voxilaprevir** is an oral fixed-dose direct-acting antiviral combination for chronic hepatitis C virus infection. It combines sofosbuvir, a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase; velpatasvir, an inhibitor of the HCV NS5A replication-complex protein; and voxilaprevir, an inhibitor of the HCV NS3/4A serine protease. Marketed by Gilead as Vosevi, it is supplied as a 400 mg/100 mg/100 mg film-coated tablet and is principally used as a 12-week retreatment regimen for adults with chronic HCV infection without cirrhosis or with compensated cirrhosis after failure of specified prior direct-acting antiviral regimens. ([gilead.com](https://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/vosevi/vosevi_pi.pdf))
- Brand names
- Vosevi
- Other names
- SOF/VEL/VOXsofosbuvir/velpatasvir/voxilaprevirsofosbuvir/velpatasvir/voxilaprevir fixed-dose combination
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on sofosbuvir + velpatasvir + voxilaprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sofosbuvir + velpatasvir + voxilaprevir.